Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645575 | 0.94 | RAB9A (0.65) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3177868 | 0.89 | RAB9A (0.66) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5352269 | 0.85 | RAB9A (0.72) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL29706525 | 0.85 | RAB9A (0.74) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2985096 | 0.85 | RAB9A (0.74) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL29538889 | 0.85 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8502308 | 0.85 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL1306777 | 0.85 | RAB9A (0.71) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2990343 | 0.84 | RAB9A (0.77) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5738051 | 0.84 | RAB9A (0.70) | RAB9ANPC1CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | RAB9A 784/4885NPC1 2011/4885CYP2C9 2123/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | RAB9A 784/4885NPC1 2011/4885CYP2C9 2123/4885 |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | RAB9A 784/4885NPC1 2011/4885CYP2C9 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.